Japan's Price Cuts Slated For April Bring Old, New Blues For Industry
Xolair, Lixiana, Keytruda Hard Hit
Next month’s regular reimbursement price cut in Japan includes some large reductions for big-selling drugs, while one new rule has been applied for the first time.
You may also be interested in...
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.
The European research-based pharma industry in Japan continues to call for a pricing system that better encourages innovation and for inclusive discussions on reforms that address health system challenges and focus on patients.
The 4 February entry deadline is looming for the inaugural Informa Pharma Intelligence Awards Japan, which will be held in Tokyo on 12 May 2022 to recognize and reward the very best innovations and achievements in pharma and biotech, highlighting Japan's integral role in the global healthcare market.